Aurobindo Reprimanded By SEBI Over US FDA Warning Disclosure
‘Very Limited And Restricted Information’ Revealed By Indian Firm Deemed ‘Insufficient’
The Securities and Exchange Board of India has warned Aurobindo that it did not disclose sufficient information about a US FDA warning letter that it received in connection with its Unit 1 API facility in Hyderabad early this year.
